Seeking AlphaCodex · 实盘不做把握 8/10
北京时间·🕒 发布 23:33:40时区推断·⟳ 抓取 23:40:12·⚡ 决策 07-31 23:42:25 +2m13s·87.8 天前
Replimune的RP1获FDA顾问委员会支持后被Seeking Alpha转述并提及Cantor上调评级
FDA顾问委员会支持RP1用于晚期黑色素瘤，对Replimune（REPL.US）本身是正面监管催化。
📄 原文Seeking Alpha↗ 原文
Replimune rebounds as positive AdCom vote prompts Cantor upgrade
On the Move Replimune rebounds as positive AdCom vote prompts Cantor upgrade Jul 31, 2026, 11:33 AM ET Replimune Group,…
不做 Replimune（REPL.US）
同一RP1黑色素瘤FDA顾问会催化已在已处理库中多次命中，且7月31日00:07 CST已有已推卡记录；本条Seeking Alpha为盘中转述和Cantor评级跟进，不重复开仓。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-30 · 扩散 high · price-in 风险 high ↗
关键理由
- FDA顾问委员会支持RP1用于晚期黑色素瘤，对Replimune（REPL.US）本身是正面监管催化。
- 但系统在本信号前已多次处理同一RP1专家会催化，其中已有一条已推卡，本条Seeking Alpha只是盘中转述和分析师评级跟进。
主要风险
- 重复消息会把同一FDA投票催化重复推送给执行端，需压住不再开新卡。
工具调用 · 历史记录,结果未知(3 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 437 字
On the Move
Replimune rebounds as positive AdCom vote prompts Cantor upgrade
Jul 31, 2026, 11:33 AM ET
Replimune Group, Inc. (REPL) Stock
By
:
Dulan Lokuwithana
,
SA News Editor
alexsl
Despite a multi-day decline earlier this week, Replimune (
REPL
) shares bounced back on Friday as Cantor Fitzgerald upgraded the biotech after an FDA advisory committee voted in favor of the company’s lead, RP1, targeted at
melanoma, a skin cancer.
On
Replimune rebounds as positive AdCom vote prompts Cantor upgrade
Jul 31, 2026, 11:33 AM ET
Replimune Group, Inc. (REPL) Stock
By
:
Dulan Lokuwithana
,
SA News Editor
alexsl
Despite a multi-day decline earlier this week, Replimune (
REPL
) shares bounced back on Friday as Cantor Fitzgerald upgraded the biotech after an FDA advisory committee voted in favor of the company’s lead, RP1, targeted at
melanoma, a skin cancer.
On
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。